Skip to main content

03-06-2022 | ASCO 2022 | Conference coverage | Video

COSMIC-021 cohorts continue to show encouraging cabozantinib–atezolizumab advanced UC activity

Sumanta Pal outlines results from three cohorts of the COSMIC-021 trial pointing to the potential of combining cabozantinib with atezolizumab in treatment-naïve and pretreated advanced urothelial cancer (2:11).

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany